Kansas 2025-2026 Regular Session

Kansas House Bill HB2369 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	Session of 2025
2	2	HOUSE BILL No. 2369
3	3	By Committee on Health and Human Services
4	4	Requested by Heather Sprague on behalf of the Kansas Association of Chain
5	5	Drugstores
6	6	2-7
7	7	AN ACT concerning health and healthcare; amending the pharmacy act of
8	8	the state of Kansas; allowing pharmacists to administer vaccines
9	9	pursuant to a vaccination protocol; amending K.S.A. 2024 Supp. 65-
10	10	1626a and repealing the existing section.
11	11	Be it enacted by the Legislature of the State of Kansas:
12	12	Section 1. K.S.A. 2024 Supp. 65-1626a is hereby amended to read as
13	13	follows: 65-1626a. (a) For the purpose of the pharmacy act of the state of
14	14	Kansas, the following individuals shall be deemed to be engaged in the
15	15	practice of pharmacy:
16	16	(1) Individuals who publicly profess to be a pharmacist, or publicly
17	17	profess to assume the duties incident to being a pharmacist and their
18	18	knowledge of drugs or drug actions, or both; and
19	19	(2) individuals who attach to their name any words or abbreviation
20	20	indicating that they are a pharmacist licensed to practice pharmacy in
21	21	Kansas.
22	22	(b) As used in this section:
23	23	(1) "Practice of pharmacy" means:
24	24	(A) The interpretation and evaluation of prescription orders;
25	25	(B) the compounding, dispensing and labeling of drugs and devices
26	26	pursuant to prescription orders;
27	27	(C) except as provided in subsection (d), the ordering and
28	28	administering of vaccine pursuant to a vaccination protocol vaccines
29	29	approved or authorized by the United States food and drug administration
30	30	to persons at least seven years of age or the age recommended by the
31	31	United States center for disease control and prevention, whichever is
32	32	older;
33	33	(D) the participation in drug selection according to state law and
34	34	participation in drug utilization reviews;
35	35	(E) the proper and safe storage of prescription drugs and prescription
36	36	devices and the maintenance of proper records thereof in accordance with
37	37	law;
38	38	(F) consultation with patients and other health care healthcare
39	39	practitioners about regarding the safe and effective use of prescription
40	40	1
41	41	2
42	42	3
43	43	4
44	44	5
45	45	6
46	46	7
47	47	8
48	48	9
49	49	10
50	50	11
51	51	12
52	52	13
53	53	14
54	54	15
55	55	16
56	56	17
57	57	18
58	58	19
59	59	20
60	60	21
61	61	22
62	62	23
63	63	24
64	64	25
65	65	26
66	66	27
67	67	28
68	68	29
69	69	30
70	70	31
71	71	32
72	72	33
73	73	34 HB 2369 2
74	74	drugs and prescription devices;
75	75	(G) performance of collaborative drug therapy management pursuant
76	76	to a written collaborative practice agreement with one or more physicians
77	77	who have an established physician-patient relationship;
78	78	(H) participation in the offering or performing of those acts, services,
79	79	operations or transactions necessary in the conduct, operation,
80	80	management and control of a pharmacy; and
81	81	(I) initiation of therapy for the conditions specified in K.S.A. 2024
82	82	Supp. 65-16,131, and amendments thereto.
83	83	(2) "Collaborative drug therapy management" means a practice of
84	84	pharmacy where in which a pharmacist performs certain pharmaceutical-
85	85	related patient care functions for a specific patient which have who has
86	86	been delegated to the pharmacist by a physician through a collaborative
87	87	practice agreement. A physician who enters into a collaborative practice
88	88	agreement is responsible for the care of the patient following initial
89	89	diagnosis and assessment and for the direction and supervision of the
90	90	pharmacist throughout the collaborative drug therapy management
91	91	process. Nothing in this subsection shall be construed to permit a
92	92	pharmacist to alter a physician's orders or directions, diagnose or treat any
93	93	disease, independently prescribe drugs or independently practice medicine
94	94	and surgery.
95	95	(3) "Collaborative practice agreement" means a written agreement or
96	96	protocol between one or more pharmacists and one or more physicians that
97	97	provides who provide for collaborative drug therapy management. Such
98	98	collaborative practice agreement shall contain certain specified conditions
99	99	or limitations pursuant to the collaborating physician's order, standing
100	100	order, delegation or protocol. A collaborative practice agreement shall be:
101	101	(A) Consistent with the normal and customary specialty, competence and
102	102	lawful practice of the physician; and (B) appropriate to the pharmacist's
103	103	training and experience.
104	104	(4) "Physician" means a person licensed to practice medicine and
105	105	surgery in this state.
106	106	(c) Nothing in this section shall be construed to:
107	107	(1) Add any additional requirements for registration or for a permit
108	108	under the pharmacy act of the state of Kansas or for approval under K.S.A.
109	109	65-1643(g), and amendments thereto;
110	110	(2) prevent persons other than pharmacists from engaging in drug
111	111	utilization review;
112	112	(3) require persons lawfully in possession of prescription drugs or
113	113	prescription devices to meet any storage or record keeping recordkeeping
114	114	requirements, except such storage and record keeping requirements as may
115	115	be otherwise provided by law; or
116	116	(4) affect any person consulting with a healthcare practitioner about
117	117	1
118	118	2
119	119	3
120	120	4
121	121	5
122	122	6
123	123	7
124	124	8
125	125	9
126	126	10
127	127	11
128	128	12
129	129	13
130	130	14
131	131	15
132	132	16
133	133	17
134	134	18
135	135	19
136	136	20
137	137	21
138	138	22
139	139	23
140	140	24
141	141	25
142	142	26
143	143	27
144	144	28
145	145	29
146	146	30
147	147	31
148	148	32
149	149	33
150	150	34
151	151	35
152	152	36
153	153	37
154	154	38
155	155	39
156	156	40
157	157	41
158	158	42
159	159	43 HB 2369 3
160	160	regarding the safe and effective use of prescription drugs or prescription
161	161	devices.
162	162	(d) A pharmacist shall not administer vaccines if such vaccination
163	163	cannot be administered pursuant to a vaccination protocol. Such vaccines
164	164	shall include the following: cholera, monkeypox, Japanese encephalitis,
165	165	typhoid, rabies, yellow fever, tick-borne encephalitis, anthrax,
166	166	tuberculosis, dengue, Hib, polio, rotavirus, smallpox and any vaccine
167	167	approved after January 1, 2023, pursuant to rules and regulations adopted
168	168	by the board of pharmacy.
169	169	Sec. 2. K.S.A. 2024 Supp. 65-1626a is hereby repealed.
170	170	Sec. 3. This act shall take effect and be in force from and after its
171	171	publication in the statute book.
172	172	1
173	173	2
174	174	3
175	175	4
176	176	5
177	177	6
178	178	7
179	179	8
180	180	9
181	181	10
182	182	11
183	183	12